Yumanity Therapeutics Inc
Change company Symbol lookup
Select an option...
YMTX Yumanity Therapeutics Inc
OTGLF CD Projekt SA
HRL Hormel Foods Corp
IPOF Social Capital Hedosophia Holdings Corp VI
NIO NIO Inc
NRT North European Oil Royalty Trust
JNJ Johnson & Johnson
STAG STAG Industrial Inc
TM Toyota Motor Corp
HSIC Henry Schein Inc
Go

Company profile

Yumanity Therapeutics Inc, formerly Proteostasis Therapeutics, Inc., is a clinical-stage biopharmaceutical company. The Company is engaged in treatment of neurodegenerative diseases through its scientific foundation and drug discovery platform. The platform is designed to enable the Company to screen for potential disease-modifying therapies by overcoming toxicity of misfolded proteins in neurogenerative diseases. The Company's product candidate, YTX-7739, is in Phase 1 clinical development for Parkinson's disease and YTX-9184, in IND-enabling studies for Dementia with Lewy Bodies. The Company’s pipeline consists of additional programs focused on multi- system atrophy, amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease), frontotemporal lobar dementia (FTLD), and Alzheimer's disease.

The symbol you entered, PTI, changed to YMTX.

Price
Delayed
$20.26
Day's Change
0.09 (0.45%)
Bid
--
Ask
--
B/A Size
--
Day's High
20.39
Day's Low
19.13
Volume
(Below Average)

Today's volume of 30,057 shares is on pace to be lower than YMTX's 10-day average volume of 62,854 shares.

30,057

Display:

Providers:

UpdateCancel
6 providers
December 22, 2020
Proteostasis Therapeutics, Inc. Stockholders Approve Business Combination with Yumanity Therapeutics, Inc.; Board Sets Reverse Stock Split Ratio

Proteostasis Therapeutics, Inc. ("Proteostasis") (Nasdaq: PTI) announced today that, based on the final vote count certified by the inspector of elections at its reconvened special meeting of stockholders held at 9:00 a.m. Eastern Time on December...(PR Newswire)

November 16, 2020
Proteostasis Therapeutics Reports Third Quarter 2020 Financial Results

Proteostasis Therapeutics, Inc. (Nasdaq:PTI), a clinical stage biopharmaceutical company, today announced financial results for the third quarter ended September 30, 2020. In August 2020, Proteostasis and Yumanity Therapeutics, Inc. ("Yumanity")...(PR Newswire)

November 13, 2020
SHAREHOLDER ALERT: Halper Sadeh LLP Reminds Shareholders About Its Investigations; Investors are Encouraged to Contact the Firm - CBMG, MVC, PTI, CGIX

Halper Sadeh LLP, a global investor rights law firm, announces it is investigating: Cellular Biomedicine Group, Inc. (NASDAQ: CBMG) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its...(Globe Newswire)

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.